Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.285
-0.025 (-1.08%)
Mar 6, 2026, 3:45 PM EST - Market open
Allogene Therapeutics Employees
As of December 31, 2024, Allogene Therapeutics had 229 total employees, including 226 full-time and 3 part-time employees. The number of employees decreased by 4 or -1.72% compared to the previous year.
Employees
229
Change (1Y)
-4
Growth (1Y)
-1.72%
Revenue / Employee
n/a
Profits / Employee
-$925,830
Market Cap
513.51M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MeiraGTx Holdings | 409 |
| ADC Therapeutics | 265 |
| uniQure | 209 |
| Rigel Pharmaceuticals | 164 |
| Prothena Corporation | 163 |
| Verastem | 78 |
| Larimar Therapeutics | 65 |
| Tectonic Therapeutic | 60 |
ALLO News
- 4 days ago - Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update - GlobeNewsWire
- 16 days ago - Allogene Therapeutics, Inc. (ALLO) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript - Seeking Alpha
- 4 weeks ago - Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T - GlobeNewsWire
- 2 months ago - Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis - GlobeNewsWire
- 4 months ago - Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T - Seeking Alpha
- 4 months ago - Allogene Therapeutics, Inc. (ALLO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update - GlobeNewsWire